Biocept (BIOC) Trading Down 0%

Shares of Biocept Inc (NASDAQ:BIOC) traded down 0% during trading on Thursday . The company traded as low as $0.29 and last traded at $0.31. 2,190,000 shares were traded during trading, a decline of 25% from the average session volume of 2,920,000 shares. The stock had previously closed at $0.31.

A number of analysts have recently commented on the stock. Zacks Investment Research raised shares of Biocept from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Chardan Capital reissued a “buy” rating and set a $1.50 target price (down previously from $2.50) on shares of Biocept in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Biocept has a consensus rating of “Hold” and a consensus target price of $1.75.

The company has a market capitalization of $19.40, a P/E ratio of -0.35 and a beta of 1.74. The company has a quick ratio of 1.27, a current ratio of 1.41 and a debt-to-equity ratio of 0.24.

An institutional investor recently bought a new position in Biocept stock. Sabby Management LLC bought a new position in shares of Biocept Inc (NASDAQ:BIOC) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 962,265 shares of the medical research company’s stock, valued at approximately $668,000. Sabby Management LLC owned approximately 1.51% of Biocept as of its most recent SEC filing. Institutional investors own 9.29% of the company’s stock.

WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.

Leave a Reply